Windlas BiotechNSE:WINDLAS -0.56%86 ROE % is 11.01% as of Mar. 2026, which is 12% below its 10-year median of 12.50. GuruFocus rates NSE:WINDLAS with a GF Score™ of 86/100 and a GF Value™ of ₹937.25 (Fairly Valued). The stock has 1 warning sign investors should review. Among 936 Drug Manufacturers companies, Windlas Biotech ranks better than 71.9% on this metric.
The historical rank and industry rank for Windlas Biotech's ROE % or its related term are showing as below:
NSE:WINDLAS'
s ROE % Range Over the Past 10 Years
Min: 7.75 Med: 12.5 Max: 32.97
Current: 12.3
During the past 8 years, Windlas Biotech's highest ROE % was 32.97%. The lowest was 7.75%. And the median was 12.50%.
NSE:WINDLAS's ROE % is ranked better than 71.9% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs NSE:WINDLAS: 12.30
Windlas Biotech (NSE:WINDLAS) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Windlas Biotech ROE % Related Terms
Windlas Biotech ROE % Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's ROE % distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Windlas Biotech (NSE:WINDLAS) has a ROE % of 11.01% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Windlas Biotech and its competitors. This is 12% below median its historical median of 12.50. Over the past decade, Windlas Biotech's ROE % has ranged from 7.75 to 32.97. According to the industry distribution chart, Windlas Biotech ranks #263 out of 936 companies in the Drug Manufacturers industry, placing it in the top 28.1%.
Is Windlas Biotech's ROE % too high?
Windlas Biotech's current ROE % of 11.01% is 12% below median its 10-year median of 12.50. Over the past 10 years, this metric has ranged from a low of 7.75 to a high of 32.97. The Drug Manufacturers industry median ROE % is 5.87. Windlas Biotech's value of 11.01% is 87.7% above this industry median. Based on the distribution chart, Windlas Biotech ranks #263 out of 936 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Windlas Biotech has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's ROE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #263 out of 936 companies for ROE %. This puts Windlas Biotech in the upper half of its industry. The industry median ROE % is 5.87. Windlas Biotech's value of 11.01% is 87.7% above this benchmark. Historically, Windlas Biotech's own ROE % has ranged from 7.75 to 32.97 over the past decade. While the company's 10-year median is 12.50 vs. the industry median of 5.87, Windlas Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windlas Biotech's current ROE % of 11.01% is 87.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Windlas Biotech and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current ROE % is 11.01%, which is 12% below median its own 10-year median of 12.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹937.25, compared to a current price of ₹859.00 — trading 8.3% below its estimated fair value. The current ROE % is 11.01%, which is 12% below median its 10-year median of 12.50 and 87.7% above the Drug Manufacturers industry median of 5.87. Windlas Biotech's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current ROE % is 11.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹859.00 is trading 8.3% below its estimated GF Value™ of ₹937.25.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
ROE %: 11.01% (12% below median its 10-year median of 12.50)
GF Value™: ₹937.25 vs. price of ₹859.00 (8.3% below fair value)
Industry Position: 87.7% above the Drug Manufacturers median (#263 of 936)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
86GF Score
Get the complete analysis for NSE:WINDLAS
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
